Shaping Tomorrow: Advancing Cancer Care and Research for Adolescents and Young Adults

Shaping Tomorrow: Advancing Cancer Care and Research for Adolescents and Young Adults is a complimentary symposium that brings together leading experts to share the latest research and innovative treatments tailored to the unique needs of the AYA cancer population. This comprehensive program provides cutting-edge insights to advance care and improve patient outcomes. The symposium will center on three core themes:

• The integration of biological discoveries into clinical application

• Innovations in supportive services to enhance quality of life

• Emerging interventional studies.

Attendees will benefit from dynamic group discussions and interactive breakout sessions led by renowned experts in the field. The program also features valuable opportunities for professional growth and community building, including networking opportunities, a thought-provoking keynote address, and special sessions designed to support interprofessional care teams.

Please note that this program will be held in person only—there is no virtual attendance option—and will take place at Memorial Sloan Kettering’s Zuckerman Research Center. A networking reception will take place at the conclusion of the program from 4:30 to 6:00 PM. Please indicate your attendance by RSVPing during the registration process.

This symposium is intended for senior and junior faculty, researchers, and healthcare professionals across multiple disciplines who are engaged in advancing adolescent and young adult cancer care. We hope you will join us as we explore the evolving landscape of AYA cancer care and work together to improve outcomes for this unique patient population.

1. Identify and discuss recent advancements in translational biology relevant to AYA oncology, with a focus on how discoveries are informing treatment strategies.
2. Evaluate current best practices in supportive care for AYA patients, with a focus on psychosocial support, symptom management, and enhancing quality of life during treatment and survivorship.
3. Examine ongoing interventional studies in AYA oncology, focusing on innovative treatment approaches, clinical trial design, and their potential impact on improving outcomes for this patient population.

While this symposium is complimentary for all participants, advance registration is required. Please select the 'Register' tab above to complete your registration and confirm your attendance.

If you are registered for this program and are no longer able to attend, please contact [email protected] to cancel you registration. Timely cancellations are important to ensure accurate planning and catering. For additional details on our cancellation terms, please review our Cancellation Policy.

Industry professionals are welcome to attend Continuing Medical Education events at MSK for their own educational purposes. View our Registration Policy for Industry Professionals for more information.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This symposium will offer the following credit types:

• AMA PRA Category 1 Credits™

• ABIM MOC Points

• ABP MOC Points

• New York State Psychology Contact Hours*

• New York State Social Work Contact Hours*

• ANCC CNE Contact Hours
  

*Not all states accept New York State Contact Hours. Please check with the licensing board in your state for guidance on their acceptance of the credit types offered for this course

Hotel Accommodations

We look forward to welcoming you to Memorial Sloan Kettering for this program. If you’ll be traveling to New York City from out of town, we recommend that you plan your overnight stay as soon as possible. To make the planning a little easier, Memorial Sloan Kettering has negotiated special rates and amenities at select hotels in Manhattan. To view the list of select hotels and additional details on each, please visit: msk.org/accommodations

Parking Information

Street parking in Manhattan is extremely limited, so you may find it more convenient to park in Memorial Sloan Kettering’s garage or in a commercial garage. For a list of parking resources around MSK, click here. Please note that wedoes not offer parking validation for course attendees.

MSK Symposium Director

Chaya Moskowitz, PhD
Attending Biostatistician

Symposium Planning Committee

Julia Glade Bender, MD
Vice Chair for Clinical Research
Department of Pediatrics
Memorial Sloan Kettering Cancer Center

Katie Devine, PhD, MPH
Associate Director of the New Jersey Pediatric Hematology and Oncology Research Center of Excellence (NJPHORCE)
Rutgers Cancer Institute
Associate Professor of Pediatrics
Section Chief of Pediatric Population Science, Outcomes, and Disparities Research, Division of Pediatric Hematology/Oncology
Rutgers Robert Wood Johnson Medical School

A. Lindsay Frazier, MD
Associate Professor, Pediatric Oncology, Dana-Farber Cancer Institute
Professor, Pediatrics, Harvard Medical School
Research Associate, Nutrition, Harvard T.H. Chan School Of Public Health

Samuel A. Funt, MD
Assistant Attending, Genitourinary Oncology Service
Memorial Sloan Kettering Cancer Center 

Asher Marks, MD
Associate Professor of Pediatrics (Hematology/Oncology)
Director, Pediatric Neuro-Oncology
Yale School of Medicine

Damon R. Reed, MD
Division Head, Pediatric Solid Tumors
Chief, Pediatric Sarcoma Service
Memorial Sloan Kettering Cancer Center 

Lisa G. Roth, MD
Professor of Pediatrics
Director, Pediatric Oncology
Weill Cornell Medicine

William D. Tap, MD
Chief, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center

Yannis K. Valtis, MD
Medical Oncology Fellow

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.